In the 1920s, when George Papanicolaou began to develop the screening test that now bears his name, the cause of cervical cancer was not known, and the cancer was a common cause of death among women. Since Papanicolaou testing entered clinical practice in the 1950s, however, cervical cancer incidence and mortality have markedly decreased in the United States. In 2014, there will be an estimated 12 360 new cases of cervical cancer and 4020 deaths attributable to the disease.1
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Feldman S. Human Papillomavirus Testing for Primary Cervical Cancer Screening: Is It Time to Abandon Papanicolaou Testing? JAMA Intern Med. 2014;174(10):1539–1540. doi:10.1001/jamainternmed.2014.4021
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: